DanCann Pharma A/S: CannGros ApS’ new facilities in Ansager have been approved by the Danish Medicines Agency for import, repackaging and distribution

COPENHAGEN, Denmark, 13 December 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that its subsidiary CannGros ApS (“CannGros”) and its new facilities in Ansager has been approved by the Danish Medicines Agency.

In October 2021, CannGros was acquired by DanCann Pharma, but until now has continued to operate from its location in Glostrup. In correlation with an inspection by the Danish Medicines Agency two weeks ago, the move to new facilities in Ansager was approved. The Company's activities will be moved to Jutland during January.

The Danish Medicines Agency spent three days on an inspection visit to DanCann Pharma in Ansager. On Tuesday and Wednesday to inspect the production facilities and quality systems at DanCann Pharma with a view to issuing the EU-GMP certification, on Thursday the subsidiary CannGros' newly furnished facilities had to be thoroughly inspected at the seams before the relocation of the company could be approved. In both cases, the inspectors from Danish Medicines Agency gave their approval.

Since its foundation in 2018, DanCann Pharma has taken massive steps towards establishing itself as a manufacturer and distributor of products on the medical cannabis market. When the Company acquired the wholesale company CannGros in the autumn 2021, DanCann Pharma became the market leader with license and sales rights for three products available on the market under the Danish Pilot Programme.

Charlotte Hagedorn Jørgensen, qualified person at CannGros, has been responsible for getting system and physical framework in place according to the Danish Medicines Agency's requirements and guidelines.

Charlotte Hagedorn Jørgensen comments:

- CannGros was the first company to be approved by the Danish Medicines Agency for the import and handling of medical cannabis under the Danish Pilot Programme back in 2018. Now we are moving the activities from Glostrup to Ansager, and we have received positive feedback from the Danish Medicines Agency in relation to our way of handling the operation of the company going forward.

The experienced industry profile Louise Conradsen is CEO of CannGros and act as the commercial profile and interface at the  DanCann Pharma group. She has successfully performed the task of establishing a well-functioning sales unit.

Louise Conradsen comments:

- CannGros has proven to be a really strong acquisition and an important addition to DanCann Pharma. We have connected the desired commercial leg to our Company, and it has already yielded results with the recently concluded distributorship agreements with German WEECO Pharma and Polish Storkpharm, which together have a value of more than DKK 80 million over the next three years.

Louise Conradsen is responsible for business development, sourcing, purchasing, supply chain and the entire task of securing long-term contracts and agreements with suppliers and customers worldwide. And then she is also responsible for the import and distribution part of the business in Denmark, which in January moves from Glostrup to Ansager.

Louise Conradsen concludes:

- We have benefited from huge goodwill from the former owners of CannGros, who have allowed us to continue the business from Glostrup. However, we look forward to being able to gather all our activities in Ansager, so that we can utilize some of the synergies that naturally lie in operating from a common location. Our team has put in a huge effort recently, and I am proud that we have now reached this goal.

For more information

Louise Conradsen, managing director at CannGros, tel.: 6916 0393

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas. DanCann Pharma is EU-GMP-approved by the Danish Medicines Agency under the Danish Pilot Programme for medical cannabis, and have, among other things, license for manufacturing, export, import and distribution.

The Company has an ambition to deliver a qualified and standardized product - prepared according to standards that apply in the manufacture of conventional medicine. The DanCann Pharma group also owns the subsidiary CannGros ApS, which is the market leader in Denmark with the import and distribution of the products Bedrocan®, Bedica® and Bediol® to all the Danish pharmacies.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and sidelisted on OTCQB Venture Market in USA (DCPXF).

For more information, visit: www.dancann.com  

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: [email protected]  

Website: www.dancann.com  

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.